(Q51470591)

5 April 2018

title

Long-term improvement of metabolic control by acarbose in type 2 diabetes patients poorly controlled with maximum sulfonylurea therapy. (English)

1 reference

5 April 2018

1 reference

Werner Bachmann

1

1 reference

5 April 2018

Dieter Petzinna

2

1 reference

5 April 2018

Sotirios A Raptis

3

1 reference

5 April 2018

Thomas Wascher

4

1 reference

5 April 2018

Torsten Westermeier

5

1 reference

5 April 2018

European Acarbose Study Group

6

1 reference

5 April 2018

publication date

1 January 2003

1 reference

5 April 2018

Clinical Drug Investigation

published in

1 reference

5 April 2018

volume

23

1 reference

5 April 2018

issue

10

1 reference

5 April 2018

page(s)

679-686

1 reference

5 April 2018

Comparison of acarbose and metformin in patients with Type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study

cites work

1 reference

12 December 2020

The Bedford survey: ten year mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycaemic controls and risk indices for coronary heart disease in borderline diabetics

1 reference

12 December 2020

Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up

1 reference

12 December 2020

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

1 reference

12 December 2020

The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.

1 reference

12 December 2020

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

1 reference

12 December 2020

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program

1 reference

12 December 2020

Relationship of postload plasma glucose to mortality with 19-yr follow-up. Comparison of one versus two plasma glucose measurements in the Chicago Peoples Gas Company Study

1 reference

12 December 2020

A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients.

1 reference

12 December 2020

Acarbose vs. bedtime NPH insulin in the treatment of secondary failures to sulphonylurea-metformin therapy in type 2 diabetes mellitus.

1 reference

12 December 2020

A desktop guide to Type 2 diabetes mellitus. European Diabetes Policy Group 1999

1 reference

12 December 2020

Combining sulfonylureas and other oral agents

1 reference

12 December 2020

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

12 December 2020

Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure: a randomised-multicentric trial in primary health-care. Diabetes and Acarbose Research Group.

1 reference

12 December 2020

A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)

1 reference

12 December 2020

The use of Acarbose in Type 2 diabetic patients in secondary failure: effects on glycaemic control and diet induced thermogenesis

1 reference

12 December 2020

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

12 December 2020

Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study

1 reference

12 December 2020

Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study

1 reference

12 December 2020

Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies

1 reference

12 December 2020

Glucosidase inhibition. A new approach to the treatment of diabetes, obesity, and hyperlipoproteinaemia

1 reference

12 December 2020

10.2165/00044011-200323100-00007

Identifiers

DOI

1 reference

5 April 2018

PubMed ID

17535083

1 reference

5 April 2018